I-Mab Biopharma Signs Agreement for Clinical Research of TJD5 in Combination Therapy

I-Mab Biopharma, a clinical stage biopharmaceutical company exclusively focused on the development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases enters into a collaboration with Roche for I-Mab’s clinical study to evaluate TJD5 in combination with atezolizumab (TECENTRIQ).

Roche will supply atezolizumab (TECENTRIQ) to I-Mab for use in clinical study in combination with TJD5. All rights generated in the study will belong jointly to I-Mab and Roche.

TJD5 is a proprietary innovative CD73 antibody from I-Mab’s discovery pipeline with best-in-class potential. CD73 is an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine, which contributes to a highly immunosuppressive tumor micro-environment. On January 18, 2019, TJD5 received IND clearance from the U.S. FDA.

Dr. Joan Shen, Head of R&D of I-Mab, commented, “We are thrilled to collaborate with Roche, a global leader of cancer immunotherapy, and we look forward to maximizing the potential of TJD5 to meet the clinical needs all over the world.”